BR112017026061A2 - composto, uso de um composto, e, método de tratamento de uma infecção viral - Google Patents

composto, uso de um composto, e, método de tratamento de uma infecção viral

Info

Publication number
BR112017026061A2
BR112017026061A2 BR112017026061-1A BR112017026061A BR112017026061A2 BR 112017026061 A2 BR112017026061 A2 BR 112017026061A2 BR 112017026061 A BR112017026061 A BR 112017026061A BR 112017026061 A2 BR112017026061 A2 BR 112017026061A2
Authority
BR
Brazil
Prior art keywords
compound
viral infection
treating
therapy
useful
Prior art date
Application number
BR112017026061-1A
Other languages
English (en)
Other versions
BR112017026061B1 (pt
Inventor
Westman Jacob
Original Assignee
Curovir Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curovir Ab filed Critical Curovir Ab
Publication of BR112017026061A2 publication Critical patent/BR112017026061A2/pt
Publication of BR112017026061B1 publication Critical patent/BR112017026061B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

um composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, útil em terapia, em particular no tratamento de uma infecção viral.
BR112017026061-1A 2015-06-24 2016-06-10 Composto, composição farmacêutica, e, uso de um composto BR112017026061B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15173687 2015-06-24
EP15173687.3 2015-06-24
PCT/EP2016/063383 WO2016206999A1 (en) 2015-06-24 2016-06-10 Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy

Publications (2)

Publication Number Publication Date
BR112017026061A2 true BR112017026061A2 (pt) 2018-08-14
BR112017026061B1 BR112017026061B1 (pt) 2023-03-28

Family

ID=53483747

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017026061-1A BR112017026061B1 (pt) 2015-06-24 2016-06-10 Composto, composição farmacêutica, e, uso de um composto

Country Status (11)

Country Link
US (1) US10407429B2 (pt)
EP (1) EP3313842B1 (pt)
JP (1) JP6689299B2 (pt)
CN (1) CN107949563B (pt)
AU (1) AU2016284638B2 (pt)
BR (1) BR112017026061B1 (pt)
CA (1) CA2989722C (pt)
HK (1) HK1254809A1 (pt)
RU (1) RU2712196C2 (pt)
WO (1) WO2016206999A1 (pt)
ZA (1) ZA201800485B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11091472B2 (en) 2016-02-26 2021-08-17 The Regents Of The University Of California PI-kinase inhibitors with anti-infective activity
US11001587B2 (en) * 2017-04-05 2021-05-11 Curovir Ab Substituted indazoles as phosphatidylinositol kinase inhibitors
EP3740489A1 (en) * 2018-01-17 2020-11-25 GlaxoSmithKline Intellectual Property Development Limited Pi4kiiibeta inhibitors
TWI811428B (zh) 2018-08-21 2023-08-11 日商杏林製藥股份有限公司 雙環雜芳香環衍生物
WO2020074160A1 (en) 2018-10-10 2020-04-16 Curovir Ab Condensed pyrimidine or pyridazine derivatives as antiviral agents
CA3115128A1 (en) * 2018-10-10 2020-04-16 Curovir Ab 2,6-dimethyl-n-((pyridin-4-yl)methyl)imidazo[1,2-b]pyridazin-8-amine and 2,5-dimethyl-n-[(pyridin-4-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine derivatives for treating viral infections
WO2020146657A1 (en) * 2019-01-11 2020-07-16 The Board Of Trustees Of The Leland Stanford Junior University Pi4-kinase inhibitors with anti-cancer activity
EP4028131B1 (en) 2019-08-20 2023-11-22 Curovir Ab Heteroaromatic compounds useful in therapy
CN113801119B (zh) * 2021-08-30 2022-09-30 新乡医学院 一种吡唑并[1,3,5]三嗪类化合物的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313124B1 (en) * 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) * 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
SI1049699T1 (en) * 1998-01-28 2004-10-31 Bristol-Myers Squibb Pharma Company Pyrazolotriazines as crf antagonists
IL148905A0 (en) * 1999-09-30 2002-09-12 Neurogen Corp Pfizer Inc Certain alkylene diamine-substituted pyrazolo{1,5,-a}-1,5-pyrimidines and pyrazolo{1,5,-a}-1,3,5-triazines
GB0716292D0 (en) * 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
FR2943058B1 (fr) 2009-03-11 2011-06-03 Centre Nat Rech Scient Derives de pyrazolo°1,5-a!-1,3,5-triazines, leur preparation et leur application en therapeutique.
US8633198B1 (en) * 2011-09-20 2014-01-21 Nant Holdings Ip, Llc Small molecule inhibitors of influenza A RNA-dependent RNA polymerase
EP2634190A1 (en) * 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhinitors
EP2634189A1 (en) 2012-03-01 2013-09-04 Lead Discovery Center GmbH Pyrazolo-triazine derivatives as selective cyclin-dependent kinase inhibitors
AU2013344716B2 (en) * 2012-11-16 2018-03-01 University Health Network Pyrazolopyrimidine compounds

Also Published As

Publication number Publication date
AU2016284638A1 (en) 2018-01-18
CA2989722A1 (en) 2016-12-29
US20180298007A1 (en) 2018-10-18
AU2016284638B2 (en) 2020-01-23
CN107949563B (zh) 2020-06-05
ZA201800485B (en) 2020-05-27
CA2989722C (en) 2023-09-19
RU2018102449A (ru) 2019-07-24
EP3313842B1 (en) 2020-04-15
JP6689299B2 (ja) 2020-04-28
BR112017026061B1 (pt) 2023-03-28
CN107949563A (zh) 2018-04-20
US10407429B2 (en) 2019-09-10
HK1254809A1 (zh) 2019-07-26
EP3313842A1 (en) 2018-05-02
JP2018522861A (ja) 2018-08-16
WO2016206999A1 (en) 2016-12-29
RU2712196C2 (ru) 2020-01-24
RU2018102449A3 (pt) 2019-08-20

Similar Documents

Publication Publication Date Title
CY1125089T1 (el) Μεθοδοι για τη θεραπεια μολυνσεων απο coronaviridae
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
CY1124368T1 (el) Μεθοδοι αυξησης της τονικης αναστολης και θεραπειας του συνδρομου angelman
EA201890731A1 (ru) Модуляторы корового белка гепатита b
MX2019009443A (es) Metodos para tratar la influenza.
CO2017002170A2 (es) Terapia de combinación para tratar un paramixovirus
CY1122805T1 (el) Ενωσεις και μεθοδοι για την αγωγη βακτηριακων λοιμωξεων
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
MX2017000408A (es) Compuestos antiproliferativos y métodos de uso de los mismos.
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
NZ730809A (en) Methods for treating filoviridae virus infections
NZ733174A (en) Quinazoline derivatives used to treat hiv
MA40403A (fr) Méthodes de traitement de paramyxovirus
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA201692358A1 (ru) Производные изоиндолина для применения в лечении вирусной инфекции
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
AU2015267099A8 (en) Use of eribulin in the treatment of cancer
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201792123A1 (ru) Лечение боли
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
MX2022006229A (es) Composiciones y metodos para el tratamiento de resistencia a la insulina.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2019006768A (es) Peptidos antimicrobianos.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/06/2016, OBSERVADAS AS CONDICOES LEGAIS